Fig 2: Expression levels of CCNG1, lncRNA-ANRIL and miR-181a-5p in cisplatin-sensitive and -resistant cell lines. Expression levels of (A) CCNG1, (B) lncRNA-ANRIL and (C) miR-181a-5p in gastric GES1 epithelial cells and HGC-27, AGS, HSC-39 and FU97 gastric cancer cell lines, and their associated drug-resistant lines. *P<0.05, **P<0.01 and ***P<0.001 vs. GES1 cells; n=3. CCNG1, cyclin G1; lncRNA, long non-coding RNA; ANRIL, CDKN2B antisense RNA 1; miR, microRNA.

Fig 3: Cell cycle distribution of FU97 and drug-resistant cell lines. Cell cycle distribution of (A) FU97 and (B) FU97 DDP-resistant cell lines was detected using flow cytometry. Expression of proteins related to the cell cycle in (C) FU97 and (D) FU97 DDP-resistant cell lines was analyzed using western blotting. ##P<0.01 and ###P<0.001 vs. shRNA-NC group; $$P<0.01 and $$$P<0.001 vs. shRNA-ANRIL + inhibitor NC; n=3. DDP, cisplatin; shRNA, short hairpin RNA; Con, control; NC, negative control; ANRIL, CDKN2B antisense RNA 1; CCNG1, cyclin G1; CCND1, cyclin D1.

Fig 4: Cell cycle distribution of HGC-27 and drug-resistant cell lines. Cell cycle distribution of (A) HGC-27 and (B) HGC-27 DDP-resistant cell lines was analyzed using flow cytometry. Expression of proteins related to the cell cycle in (C) HGC-27 and (D) HGC-27 DDP-resistant cell lines was analyzed using western blotting. #P<0.05 and ###P<0.001 vs. shRNA-NC; $P<0.05, $$P<0.01 and $$$P<0.001 vs. shRNA-ANRIL + inhibitor NC; n≥3. DDP, cisplatin; shRNA, short hairpin RNA; Con, control; NC, negative control; ANRIL, CDKN2B antisense RNA 1; CCNG1, cyclin G1; CCND1, cyclin D1.